List of Publications by Year in descending order

125 papers	21,937 citations	117453 34 h-index	16605 123 g-index
131 all docs	131 docs citations	131 times ranked	25418 citing authors

#	Article	IF	Citations
1	Cancer statistics in China, 2015. Ca-A Cancer Journal for Clinicians, 2016, 66, 115-132.	157.7	14,374
2	Changing cancer survival in China during 2003â€“15: a pooled analysis of 17 population-based cancer registries. The Lancet Global Health, 2018, 6, e555-e567.	2.9	907
3	Genetic landscape of esophageal squamous cell carcinoma. Nature Genetics, 2014, 46, 1097-1102.	9.4	600
4	Challenges to effective cancer control in China, India, and Russia. Lancet Oncology, The, 2014, 15, 489-538.	5.1	411
5	LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma. Gut, 2014, 63, 1700-1710.	6.1	385
6	Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Nonâ€“Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. JAMA Oncology, 2019, 5, 696.	3.4	380
7	Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Nonâ€“Small Cell Lung Cancer Using a Clinicogenomic Database. JAMA - Journal of the American Medical Association, 2019, 321, 1391.	3.8	370
8	Epidemiology of Lung Cancer. Surgical Oncology Clinics of North America, 2016, 25, 439-445.	0.6	347
9	Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis. Molecular Cell, 2016, 61, 705-719.	4.5	319
10	KAT2A coupled with the Î±-KGDH complex acts as a histone H3 succinyltransferase. Nature, 2017, 552, 273-277.	13.7	301
11	Report of incidence and mortality in China cancer registries, 2009. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2013, 25, 10-21.	0.7	219
12	Prognostic alternative mRNA splicing signature in non-small cell lung cancer. Cancer Letters, 2017, 393, 40-51.	3.2	214
13	The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Letters, 2020, 470, 95-105.	3.2	193
14	National cancer incidence and mortality in China, 2012. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 1-11.	0.7	193
15	Long non-coding RNA NKILA inhibits migration and invasion of non-small cell lung cancer via NF-ÎºB/Snail pathway. Journal of Experimental and Clinical Cancer Research, 2017, 36, 54.	3.5	116
16	Influence of number of metastatic lymph nodes on survival of curative resected thoracic esophageal cancer patients and value of radiotherapy: Report of 549 cases. International Journal of Radiation Oncology Biology Physics, 2005, 62, 82-90.	0.4	107
17	Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nature Communications, 2021, 12, 6770.	5.8	105
18	Novel long noncoding RNA NMR promotes tumor progression via NSUN2 and BPTF in esophageal squamous cell carcinoma. Cancer Letters, 2018, 430, 57-66.	3.2	92

#	Article	IF	Citations
19	Combination of platelet count and mean platelet volume (COP-MPV) predicts postoperative prognosis in both resectable early and advanced stage esophageal squamous cell cancer patients. Tumor Biology, 2016, 37, 9323-9331.	0.8	81
20	Development and validation of an immuneâ€related prognostic signature in lung adenocarcinoma. Cancer Medicine, 2020, 9, 5960-5975.	1.3	79
21	METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding. Nature Communications, 2021, 12, 3803.	5.8	74
22	Immune signature profiling identified predictive and prognostic factors for esophageal squamous cell carcinoma. OncoImmunology, 2017, 6, e1356147.	2.1	69
23	Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance. Cell Death and Disease, 2018, 9, 759.	2.7	69
24	The TGFÎ²-induced lncRNA TBILA promotes non-small cell lung cancer progression in vitro and in vivo via cis-regulating HGAL and activating S100A7/JAB1 signaling. Cancer Letters, 2018, 432, 156-168.	3.2	68
25	Systemic immuneâ€inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected nonâ€small cell lung cancer. Thoracic Cancer, 2019, 10, 761-768.	0.8	63
26	Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma. Cancer Letters, 2020, 479, 31-41.	3.2	57
27	Identification of Isocitrate Dehydrogenase 1 as a Potential Diagnostic and Prognostic Biomarker for Non-small Cell Lung Cancer by Proteomic Analysis. Molecular and Cellular Proteomics, 2012, 11, M111.008821.	2.5	52
28	Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma. EBioMedicine, 2020, 59, 102959.	2.7	51
29	A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy. Medical Oncology, 2013, 30, 343.	1.2	50
30	Surgical Outcomes of Synchronous Multiple Primary Non-Small Cell Lung Cancers. Scientific Reports, 2016, 6, 23252.	1.6	44
31	TGF-Î²-induced NKILA inhibits ESCC cell migration and invasion through NF-Î°B/MMP14 signaling. Journal of Molecular Medicine, 2018, 96, 301-313.	1.7	44
32	A MicroRNA Signature Predicts Survival in Early Stage Small-Cell Lung Cancer Treated with Surgery and Adjuvant Chemotherapy. PLoS ONE, 2014, 9, e91388.	1.1	39
33	MiR-652-3p is upregulated in non-small cell lung cancer and promotes proliferation and metastasis by directly targeting Lgl1. Oncotarget, 2016, 7, 16703-16715.	0.8	38
34	Independent and joint associations of blood lipids and lipoproteins with lung cancer risk in Chinese males: A prospective cohort study. International Journal of Cancer, 2019, 144, 2972-2984.	2.3	38
35	PLAU directs conversion of fibroblasts to inflammatory cancer-associated fibroblasts, promoting esophageal squamous cell carcinoma progression via uPAR/Akt/NF-Î°B/IL8 pathway. Cell Death Discovery, 2021, 7, 32.	2.0	38
36	Isocitrate Dehydrogenase 1 Is a Novel Plasma Biomarker for the Diagnosis of Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2013, 19, 5136-5145.	3.2	37

#	Article	IF	Citations
37	Transcriptome profiling of lncRNA and co-expression networks in esophageal squamous cell carcinoma by RNA sequencing. Tumor Biology, 2016, 37, 13091-13100.	0.8	36
38	AJUBA promotes the migration and invasion of esophageal squamous cell carcinoma cells through upregulation of MMP10 and MMP13 expression. Oncotarget, 2016, 7, 36407-36418.	0.8	35
39	Interferon-inducible lncRNA IRF1-AS represses esophageal squamous cell carcinoma by promoting interferon response. Cancer Letters, 2019, 459, 86-99.	3.2	34
40	Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer. Cancer Biology and Medicine, 2020, 17, 768-781.	1.4	33
41	Decreased 5-hydroxymethylcytosine levels correlate with cancer progression and poor survival: a systematic review and meta-analysis. Oncotarget, 2017, 8, 1944-1952.	0.8	32
42	A Prospective Follow-up Study of the Relationship between C-Reactive Protein and Human Cancer Risk in the Chinese Kailuan Female Cohort. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 459-465.	1.1	31
43	Postoperative Intensity-Modulated Radiotherapy Improved Survival in Lymph Node-Positive or Stage III Thoracic Esophageal Squamous Cell Carcinoma. Oncology Research and Treatment, 2015, 38, 97-102.	0.8	31
44	Cohort Profile: The China Metal-Exposed Workers Cohort Study (Jinchang Cohort). International Journal of Epidemiology, 2017, 46, dyw223.	0.9	29
45	KRASâ€G12D mutation drives immune suppression and the primary resistance of antiâ€PDâ€1/PDâ€L1 immunotherapy in nonâ€small cell lung cancer. Cancer Communications, 2022, 42, 828-847.	3.7	29
46	Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma. Cancer Letters, 2020, 483, 46-58.	3.2	28
47	Histone Methylation in Nickel-Smelting Industrial Workers. PLoS ONE, 2015, 10, e0140339.	1.1	28
48	Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer. BMC Medicine, 2022, 20, 187.	2.3	28
49	Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma. Nature Communications, 2020, 11, 4878.	5.8	27
50	The association between fasting blood glucose and the risk of primary liver cancer in Chinese males: a population-based prospective study. British Journal of Cancer, 2017, 117, 1405-1411.	2.9	26
51	Aberrant methylation of EYA4 promotes epithelialâ€mesenchymal transition in esophageal squamous cell carcinoma. Cancer Science, 2018, 109, 1811-1824.	1.7	26
52	PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing. Cancer Medicine, 2019, 8, 2429-2441.	1.3	26
53	LAMC1 upregulation via TGFÎ² induces inflammatory cancerâ€associated fibroblasts in esophageal squamous cell carcinoma via NFâ€ÎºBâ€“CXCL1â€“STAT3. Molecular Oncology, 2021, 15, 3125-3146.	2.1	26
54	S100A7 as a potential diagnostic and prognostic biomarker of esophageal squamous cell carcinoma promotes M2 macrophage infiltration and angiogenesis. Clinical and Translational Medicine, 2021, 11, e459.	1.7	26

#	Article	IF	Citations
55	PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy. Journal of Cancer Research and Clinical Oncology, 2019, 145, 3055-3065.	1.2	24
56	Xerophilusin B Induces Cell Cycle Arrest and Apoptosis in Esophageal Squamous Cell Carcinoma Cells and Does Not Cause Toxicity in Nude Mice. Journal of Natural Products, 2015, 78, 10-16.	1.5	23
57	Associations of PGK1 promoter hypomethylation and PGK1â€mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA panâ€cancer analysis. Cancer Communications, 2019, 39, 1-17.	3.7	23
58	Postoperative Radiotherapy in Pathological T2â€“3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study. Oncologist, 2020, 25, e701-e708.	1.9	23
59	Calcification of arteries supplying the gastric tube increases the risk of anastomotic leakage after esophagectomy with cervical anastomosis. Journal of Thoracic Disease, 2016, 8, 3551-3562.	0.6	22
60	Long non-coding RNA GAS5 is induced by interferons and plays an antitumor role in esophageal squamous cell carcinoma. Cancer Medicine, 2018, 7, 3157-3167.	1.3	22
61	Combined detection of aneuploid circulating tumorâ€derived endothelial cells and circulating tumor cells may improve diagnosis of early stage nonâ€smallâ€cell lung cancer. Clinical and Translational Medicine, 2020, 10, e128.	1.7	22
62	Elevated TOP2A and UBE2C expressions correlate with poor prognosis in patients with surgically resected lung adenocarcinoma: a study based on immunohistochemical analysis and bioinformatics. Journal of Cancer Research and Clinical Oncology, 2020, 146, 821-841.	1.2	22
63	Loss of 5-Hydroxymethylcytosine Is an Independent Unfavorable Prognostic Factor for Esophageal Squamous Cell Carcinoma. PLoS ONE, 2016, 11, e0153100.	1.1	22
64	ERO1L promotes IL6/sIL6R signaling and regulates MUC16 expression to promote CA125 secretion and the metastasis of lung cancer cells. Cell Death and Disease, 2020, 11, 853.	2.7	21
65	An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma. Signal Transduction and Targeted Therapy, 2020, 5, 182.	7.1	21
66	Association between preâ€diagnostic serum albumin and cancer risk: Results from a prospective populationâ€based study. Cancer Medicine, 2021, 10, 4054-4065.	1.3	20
67	Association Between Sputum Atypia and Lung Cancer Risk in an Occupational Cohort in Yunnan, China. Chest, 2009, 135, 778-785.	0.4	19
68	Lymph node dissection and recurrent laryngeal nerve protection in minimally invasive esophagectomy. Annals of the New York Academy of Sciences, 2020, 1481, 20-29.	1.8	19
69	A threeâ€lncRNA signature of pretreatment biopsies predicts pathological response and outcome in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy. Clinical and Translational Medicine, 2020, 10, e156.	1.7	19
70	Knockdown of KLF5 promotes cisplatinâ€induced cell apoptosis via regulating DNA damage checkpoint proteins in nonâ€small cell lung cancer. Thoracic Cancer, 2019, 10, 1069-1077.	0.8	18
71	RNA N⁶â€methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: Current landscape and therapeutic potential. Clinical and Translational Medicine, 2021, 11, e525.	1.7	18
72	Reproductive factors and risk of type 2 diabetes in an occupational cohort of Chinese women. Journal of Diabetes and Its Complications, 2016, 30, 1217-1222.	1.2	17

#	Article	IF	Citations
73	TGF-Î²-induced PLEK2 promotes metastasis and chemoresistance in oesophageal squamous cell carcinoma by regulating LCN2. Cell Death and Disease, 2021, 12, 901.	2.7	17
74	Development and validation of clinical diagnostic models for the probability of malignancy in solitary pulmonary nodules. Thoracic Cancer, 2014, 5, 162-168.	0.8	16
75	A propensity-score matching analysis comparing long-term survival of surgery alone and postoperative treatment for patients in node positive or stage III esophageal squamous cell carcinoma after R0 esophagectomy. Radiotherapy and Oncology, 2019, 140, 159-166.	0.3	16
76	Tumor microenvironment characterization identifies two lung adenocarcinoma subtypes with specific immune and metabolic state. Cancer Science, 2020, 111, 1876-1886.	1.7	16
77	Lung cancer risk prediction models based on pulmonary nodules: A systematic review. Thoracic Cancer, 2022, 13, 664-677.	0.8	16
78	Stair-Climbing Test Predicts Postoperative Cardiopulmonary Complications and Hospital Stay in Patients with Non-Small Cell Lung Cancer. Medical Science Monitor, 2017, 23, 1436-1441.	0.5	15
79	Nickel-exposed workers in China: a cohort study. Biomedical and Environmental Sciences, 2014, 27, 208-11.	0.2	15
80	Metabolic Syndrome Components and the Risk of Colorectal Cancer: A Population-Based Prospective Study in Chinese Men. Frontiers in Oncology, 2019, 9, 1047.	1.3	14
81	A retrospective cohort mortality study in Jinchang, the largest nickel production enterprise in China. Biomedical and Environmental Sciences, 2014, 27, 567-71.	0.2	14
82	Risk prediction model for lung cancer incorporating metabolic markers: Development and internal validation in a Chinese population. Cancer Medicine, 2020, 9, 3983-3994.	1.3	13
83	Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis. Frontiers in Immunology, 2022, 13, 783495.	2.2	13
84	Prognostic factors in curatively resected pathological stage I lung adenocarcinoma. Journal of Thoracic Disease, 2017, 9, 5267-5277.	0.6	12
85	Monoacylglycerol Lipase Knockdown Inhibits Cell Proliferation and Metastasis in Lung Adenocarcinoma. Frontiers in Oncology, 2020, 10, 559568.	1.3	12
86	<scp>PDâ€L1</scp> and <scp>CD47</scp> coâ€expression predicts survival and enlightens future dualâ€targeting immunotherapy in nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 1743-1751.	0.8	12
87	Residual lymph node status is an independent prognostic factor in esophageal squamous cell Carcinoma with pathologic T0 after preoperative radiotherapy. Radiation Oncology, 2015, 10, 142.	1.2	11
88	Utility of isocitrate dehydrogenase 1 as a serum protein biomarker for the early detection of nonâ€smallâ€cell lung cancer: A multicenter in vitro diagnostic clinical trial. Cancer Science, 2020, 111, 1739-1749.	1.7	11
89	Acetyl-macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762. Toxicology and Applied Pharmacology, 2019, 365, 71-83.	1.3	10
90	The membrane-bound and soluble form of melanotransferrin function independently in the diagnosis and targeted therapy of lung cancer. Cell Death and Disease, 2020, 11, 933.	2.7	9

#	Article	IF	Citations
91	The therapeutic significance of the novel photodynamic material TPE-IQ-2O in tumors. Aging, 2021, 13, 1383-1409.	1.4	9
92	The impact of positive cancer family history on the clinical features and outcome of patients with non-small cell lung cancer. Familial Cancer, 2011, 10, 331-336.	0.9	8
93	Unilateral absence of pulmonary artery associated with contralateral lung cancer. Journal of Thoracic Disease, 2016, 8, E942-E946.	0.6	8
94	Preoperative systemic immune-inflammation index predicts survival and recurrence in patients with resected primary pulmonary sarcomatoid carcinoma. Translational Lung Cancer Research, 2021, 10, 18-31.	1.3	8
95	<scp>BMI</scp> changes and the risk of lung cancer in male neverâ€smokers: A prospective cohort study. Cancer Medicine, 2022, 11, 1336-1346.	1.3	8
96	The association between fasting blood glucose trajectory and cancer risk in Chinese population without diabetes. International Journal of Cancer, 2020, 147, 958-966.	2.3	7
97	Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma. Cellular Oncology (Dordrecht), 2020, 43, 681-694.	2.1	7
98	The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma. Cancer Biology and Medicine, 2021, 18, 562-568.	1.4	7
99	Dynamic Changes in DNA Damage and Repair Biomarkers with Employment Length among Nickel Smelting Workers. Biomedical and Environmental Sciences, 2015, 28, 679-82.	0.2	7
100	The TGFÎ²-Induced Long Non-coding RNA TBULC Promotes the Invasion and Migration of Non-small Cell Lung Cancer Cells and Indicates Poor Prognosis. Frontiers in Oncology, 2019, 9, 1340.	1.3	6
101	Development of a risk score for colorectal cancer in Chinese males: A prospective cohort study. Cancer Medicine, 2020, 9, 816-823.	1.3	6
102	Multimodality Treatment of Pulmonary Sarcomatoid Carcinoma: A Review of Current State of Art. Journal of Oncology, 2022, 2022, 1-11.	0.6	6
103	Transmembrane Protein-Based Risk Model and H3K4me3 Modification Characteristics in Lung Adenocarcinoma. Frontiers in Oncology, 2022, 12, 828814.	1.3	6
104	Translational value of IDH1 and DNA methylation biomarkers in diagnosing lung cancers: a novel diagnostic panel of stage and histology-specificity. Journal of Translational Medicine, 2019, 17, 430.	1.8	5
105	Enhanced expression of queuine tRNA-ribosyltransferase 1 (QTRT1) predicts poor prognosis in lung adenocarcinoma. Annals of Translational Medicine, 2020, 8, 1658-1658.	0.7	5
106	An immune-related lncRNA signature predicts prognosis and adjuvant chemotherapeutic response in patients with small-cell lung cancer. Cancer Cell International, 2021, 21, 691.	1.8	5
107	The Deubiquitinase USP13 Maintains Cancer Cell Stemness by Promoting FASN Stability in Small Cell Lung Cancer. Frontiers in Oncology, 0, 12, .	1.3	5
108	Dynamic variation of histone H3 trimethyl Lys4 (H3K4me3) and heterochromatin protein 1 (HP1) with employment length in nickel smelting workers. Biomarkers, 2017, 22, 420-428.	0.9	4

#	Article	IF	Citations
109	The prognostic value of tumor deposits and the impact on the TNM classification system in esophageal cancer patients. Journal of Surgical Oncology, 2021, 123, 891-903.	0.8	4
110	Development and external validation of a composite immune-clinical prognostic model associated with EGFR mutation in East-Asian patients with lung adenocarcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110069.	1.4	4
111	Rabdocoestin B exhibits antitumor activity by inducing G2/M phase arrest and apoptosis in esophageal squamous cell carcinoma. Cancer Chemotherapy and Pharmacology, 2018, 81, 469-481.	1.1	3
112	Stiffness heterogeneity-induced double-edged sword behaviors of carcinoma-associated fibroblasts in antitumor therapy. Science China Materials, 2019, 62, 873-884.	3.5	3
113	Tumorâ€infiltrating CD8⁺ T cell is prognostic and predicts adjuvant chemotherapy benefit in patients with limitedâ€stage small cell esophageal carcinoma. Clinical and Translational Medicine, 2021, 11, e456.	1.7	3
114	Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 745769.	2.2	3
115	Recurrence risk stratification based on a competing-risks nomogram to identify patients with esophageal cancer who may benefit from postoperative radiotherapy. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110619.	1.4	3
116	Pan-cancer analysis combined with experiments explores the oncogenic role of spindle apparatus coiled-coil protein 1 (SPDL1). Cancer Cell International, 2022, 22, 49.	1.8	3
117	Mammographic density and associated predictive factors for Chinese women. Breast Journal, 2018, 24, 444-445.	0.4	2
118	Adjuvant immunotherapy in resected esophageal squamous cell carcinoma: a gospel to the non-pCRs. Signal Transduction and Targeted Therapy, 2021, 6, 314.	7.1	2
119	A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic response prediction in patients with stage I lung adenocarcinoma. Cancer Biology and Medicine, 2021, 18, 734-749.	1.4	2
120	<scp>PSC</scp> subtyping based on <scp>TTF</scp>â€1 and p40 expression reveals distinct molecular characteristics and therapeutic strategies. International Journal of Cancer, 2022, 151, 717-729.	2.3	2
121	Clinical application of exclusive right-thoracic approach in surgery with or without laparotomy for mid-upper esophageal cancer. Chinese Journal of Clinical Oncology, 2008, 5, 64-66.	0.0	1
122	Application of video-assisted thoracic surgery in the standard operation for lung tumors. Clinical Oncology and Cancer Research, 2010, 7, 310-316.	0.1	0
123	Response to comment on â€˜Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinomaâ€™. Cancer Letters, 2020, 494, 5-6.	3.2	0
124	Treatment patterns, clinical outcomes, and healthcare resource use associated with advanced/metastatic lung cancer in China: protocol for a retrospective observational study. Translational Lung Cancer Research, 2020, 9, 2460-2468.	1.3	0
125	Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 782106.	2.2	0